# Safety, Tolerability and Efficacy of DEXDOR in Pediatric Patients in ICU

> **NCT03813277** · PHASE4 · COMPLETED · sponsor: **Orion Corporation, Orion Pharma** · enrollment: 60 (actual)

## Conditions studied

- ICU Sedation

## Interventions

- **DRUG:** Dexmedetomidine

## Key facts

- **NCT ID:** NCT03813277
- **Lead sponsor:** Orion Corporation, Orion Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-03-21
- **Primary completion:** 2018-05-21
- **Final completion:** 2018-05-21
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2019-01-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03813277

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03813277, "Safety, Tolerability and Efficacy of DEXDOR in Pediatric Patients in ICU". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03813277. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*